A new breakthrough in breast cancer treatment has emerged with the discovery of a promising vaccine that has shown potential in combating an aggressive form of the disease. This groundbreaking vaccine, developed by experts at Washington University School of Medicine in St. Louis, was tested in a clinical trial in the US for women with triple-negative breast cancer. The vaccine, known as a neoantigen DNA vaccine, demonstrated positive results in the study, which has been published in Genome Medicine.
In the trial, 18 participants diagnosed with non-metastatic triple-negative breast cancer were administered three doses of the experimental vaccine alongside standard treatment. The vaccine, designed to target specific tumour mutations and activate immune cells to attack abnormal cells carrying these mutations, was well-tolerated by the patients and generated significant immune responses. Remarkably, 14 patients exhibited positive immune reactions to the vaccine, and 16 remained free of tumours after a three-year follow-up period.
Although the main focus of this early-stage trial was to establish the safety of the vaccine, rather than its efficacy, the researchers compared their results with historical data of similar patients who received standard care alone. Study senior author Professor William Gillanders expressed optimism about the trial findings, describing them as better than expected. He highlighted the ongoing randomised controlled trials that aim to directly compare the standard of care plus the vaccine with standard care alone, further advancing research in this area.
Triple-negative breast cancer, known for its aggressive nature and lack of targeted therapies, typically requires treatments such as surgery, chemotherapy, and radiation therapy. The participants in the trial were considered at high risk of recurrence post-surgery due to residual tumours after initial chemotherapy. The research team’s approach involved analysing the patients’ tumour tissue to identify unique genetic mutations, then modifying the proteins in the cancer cells to enable the immune system to target the tumour while preserving healthy tissue.
By utilising their software to select neoantigens from the patients’ tumours that are likely to trigger a strong immune response, each vaccine was tailored to include an average of 11 neoantigens specific to the individual’s tumour. The team’s software tools, aimed at assisting cancer researchers and clinicians worldwide in designing personalised cancer vaccines, have been published concurrently with the study. Professor Malachi Griffith, co-leader of the software development, emphasised the potential of these tools in advancing cancer vaccine design and promoting broader use of this technology.
The Washington University School of Medicine is actively conducting several research projects on cancer vaccines, with some trials focusing on personalised vaccines for breast cancer patients combined with immunotherapies like checkpoint inhibitors. Prof Gillanders remains hopeful about the future of these treatments, expressing enthusiasm for the promise of neoantigen vaccines and their potential to enhance treatment outcomes for patients with aggressive cancers.
In conclusion, this innovative vaccine trial offers a glimmer of hope for breast cancer patients, particularly those with triple-negative breast cancer. The results of this study highlight the progress being made in developing personalised vaccine strategies to combat challenging forms of cancer, underscoring the importance of ongoing research and advancements in cancer treatment.